Gonadotropin stimulation following GnRH-a priming for poor responders in in vitro fertilization–embryo transfer programs

The effect of gonadotropin-releasing hormone agonist (GnRH-a) administration before gonadotropin super-ovulation on the stimulation characteristics of poor responder patients was assessed in an in vitro fertilization (IVF) program. Thirty consecutive patients who had exhibited low ovarian response (fewer than four retrieved oocytes) in at least two previous IVF cycles (control cycles, n = 60), were eligible for the study. GnRH-a (nafarelin) was administered daily for 7–10 days from the mid-luteal phase of the previous cycle until the first day of menstruation. Menotropin treatment was commenced on cycle day 3 (with no additional GnRH-a) (study cycles, n = 39). A significantly higher number of oocytes was retrieved (p < 0.0002) and a higher number of embryos transferred (p < 0.003) in the study cycles than in the control cycles. No cases of premature luteinizing hormone surge were recorded. Pregnancy rates per embryo transfer and per cycle were 10.4% and 7.7% for the study cycles and 2.8% and 1.6% for the control cycles, respectively. GnRH-a, administered prior to gonadotropin treatment, should be an additional option of ovulation induction protocol for poor responders in IVF programs.

[1]  S. Oehninger,et al.  Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. , 1998, Fertility and sterility.

[2]  R. Fanchin,et al.  A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. , 1996, Human reproduction.

[3]  Ferring Ab Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin , 1996 .

[4]  Z. Ben-Rafael,et al.  The poor-responder patient in an in vitro fertilization-embryo transfer (IVF-ET) program. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[5]  Z. Ben-Rafael,et al.  Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. , 1994, Fertility and sterility.

[6]  M. Filicori Ovulation Induction: Basic Science and Clinical Advances , 1994 .

[7]  S. Lipitz,et al.  Ovarian hyporesponsiveness in combined gonadotropin‐releasing hormone agonist and menotropin therapy is associated with low serum follicle‐stimulating hormone levels , 1992, Fertility and sterility.

[8]  C. Wood,et al.  A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients. , 1991, Fertility and sterility.

[9]  S. Leeder,et al.  Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. , 1986, The Journal of clinical endocrinology and metabolism.

[10]  D. Baird,et al.  Specific binding of luteinizing hormone releasing hormone to human luteal tissue , 1983 .

[11]  R. Casper,et al.  Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility. , 1982, Fertility and sterility.